Friday, April 05, 2019 7:47:43 PM
SALT LAKE CITY, April 3, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has filed suit against Clarus Therapeutics, Inc. ("Clarus") in the United States District Court ("Delaware") alleging that Clarus's JATENZO(R) product infringes six of Lipocine's U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390; 6,569,463; and 6,923,988.
"We have invested significant resources in developing innovations that have led to our importantly held strong intellectual property rights. We will defend those rights when infringed upon," said Dr. Mahesh Patel, Chairman, President and Chief Executive Officer of Lipocine.
About Lipocine
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes four development programs: TLANDO, LPCN 1144, LPCN 1111 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. LPCN 1144, an oral product of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of NASH. LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com
Forward-Looking Statements
This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding Lipocine's product candidates and related clinical trials, the timing of completion of clinical trials, the potential uses and benefits of our product candidates, and our product development efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-seeks-injunction-against-the-marketing-of-clarus-therapeutics-jatenzo-for-testosterone-replacement-therapy-300823892.html
SOURCE Lipocine Inc.
/CONTACT: Morgan Brown, Executive Vice President & Chief Financial Officer, Phone: (801) 994-7383, mb@lipocine.com, Investors: Hans Vitzthum, Phone: (617) 535-7743, hans@lifesciadvisors.com
/Web site: http://www.lipocine.com
> Dow Jones Newswires
April 03, 2019 09:34 ET (13:34 GMT)
Recent LPCN News
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 • PR Newswire (US) • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 10:06:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 10:03:08 AM
- Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 • PR Newswire (US) • 05/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 10:15:30 AM
- Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 • PR Newswire (US) • 05/01/2024 12:00:00 PM
- Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity • PR Newswire (US) • 04/11/2024 11:00:00 AM
- Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis • PR Newswire (US) • 03/28/2024 12:00:00 PM
- Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 • PR Newswire (US) • 03/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 10:31:06 PM
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 • PR Newswire (US) • 03/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:08:06 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 11:07:26 AM
- Lipocine to Present at 36th Annual Roth Conference • PR Newswire (US) • 03/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 11:01:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:10:26 PM
- Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 • PR Newswire (US) • 02/06/2024 01:00:00 PM
- Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 01:20:46 PM
- Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada • PR Newswire (US) • 01/18/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 03:00:12 PM
- Lipocine to Present at Biotech Showcase 2024 • PR Newswire (US) • 12/19/2023 01:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/22/2023 09:15:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 07:45:33 PM
- Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 • PR Newswire (US) • 11/13/2023 07:45:00 PM
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM